결정다형
☞ 결정형 발명
★ polymorph 결정다형
[내용] 결정의 구성 단위가 같고 그 배열 상태만 다른 것.
* The Korean patent examination guidelines describe that "As to an invention relating to a polymorphism, it is general to review the existence of the polymorphism in order to design formulations. Thus, if the polymorphism has a qualitatively different effect from the known compound or has a quantitatively remarkable difference, the invention relating to a specified crystal form shall be regarded as having an inventive step." Thus, for the superior effects, such as solubility, bioavailability, or storage safety data, it is recommendable for them to be described in the original specification.
* One of the Supreme Court's decisions decided that if the detailed description clearly describes that the polymorphism has such an effect, comparative experimental data with the cited reference is not required at filing. When the effect of the polymorphism is doubtful, the effect shall be specifically asserted and proven by submission of comparative experimental data (Supreme Court's Decision No. 2010HU2865 decided on July 14, 2011).
However, we think that this acceptability depends on the examiner's discretion. Recently, many examiners have requested that quantitative data therefor be described in the original specification. Thus, it is recommendable to describe superior effects together with quantitative data therefor in the original specification.
* However, if a certain compound has polymorphism, since a person skilled in the art can obtain a new crystalline form, which is not well-known, by changing the reaction conditions for production, such as solvent and temperature, to obtain crystals, the properties of a monocrystalline form are not regarded as being clearly described until the properties of the new crystalline form are specified by measurements of XRD or DSC analysis.
* An inventive step of an invention relating to a polymorph is not denied only if it has qualitatively different effects or otherwise quantitatively remarkable effects from known compounds of the prior art, if nothing out of the ordinary occurs. In this regard, the detailed description of the polymorph related invention should specifically describe such effects as above, and even though they are not experimental data compared to the prior art, it can be taken into account when determining an inventive step. If the effects of the polymorph are doubtful, the applicant or the patentee should assert and prove the effects by submission of comparative experimental data and the like after the filing date (Supreme Court's Decision No. 2010HU2865 decided on July 14, 2011).
★ polymorph 결정다형
[내용] 결정의 구성 단위가 같고 그 배열 상태만 다른 것.
* The Korean patent examination guidelines describe that "As to an invention relating to a polymorphism, it is general to review the existence of the polymorphism in order to design formulations. Thus, if the polymorphism has a qualitatively different effect from the known compound or has a quantitatively remarkable difference, the invention relating to a specified crystal form shall be regarded as having an inventive step." Thus, for the superior effects, such as solubility, bioavailability, or storage safety data, it is recommendable for them to be described in the original specification.
* One of the Supreme Court's decisions decided that if the detailed description clearly describes that the polymorphism has such an effect, comparative experimental data with the cited reference is not required at filing. When the effect of the polymorphism is doubtful, the effect shall be specifically asserted and proven by submission of comparative experimental data (Supreme Court's Decision No. 2010HU2865 decided on July 14, 2011).
However, we think that this acceptability depends on the examiner's discretion. Recently, many examiners have requested that quantitative data therefor be described in the original specification. Thus, it is recommendable to describe superior effects together with quantitative data therefor in the original specification.
* However, if a certain compound has polymorphism, since a person skilled in the art can obtain a new crystalline form, which is not well-known, by changing the reaction conditions for production, such as solvent and temperature, to obtain crystals, the properties of a monocrystalline form are not regarded as being clearly described until the properties of the new crystalline form are specified by measurements of XRD or DSC analysis.
* An inventive step of an invention relating to a polymorph is not denied only if it has qualitatively different effects or otherwise quantitatively remarkable effects from known compounds of the prior art, if nothing out of the ordinary occurs. In this regard, the detailed description of the polymorph related invention should specifically describe such effects as above, and even though they are not experimental data compared to the prior art, it can be taken into account when determining an inventive step. If the effects of the polymorph are doubtful, the applicant or the patentee should assert and prove the effects by submission of comparative experimental data and the like after the filing date (Supreme Court's Decision No. 2010HU2865 decided on July 14, 2011).